乙型肝炎病毒rtN238H 变异与阿德福韦酯耐药的相关性研究*

doi:10.3969/j.issn.1672-5069.2011.05.003

实用肝脏病杂志 ›› 2011, Vol. 14 ›› Issue (5): 327-329.doi: 10.3969/j.issn.1672-5069.2011.05.003

乙型肝炎病毒rtN238H 变异与阿德福韦酯耐药的相关性研究^*

朱华,钟彦伟,许智慧,刘佳慧,刘妍,苏何玲,徐东平

541004 广西壮族自治区桂林市桂林医学院生物技术学院（朱华，苏何玲）；北京解放军第302医院肝衰竭诊疗研究中心病毒性肝炎研究室（钟彦伟，许智慧，刘佳慧，刘妍，徐东平）

收稿日期:2011-04-20 出版日期:2011-10-15 发布日期:2016-04-14
通讯作者: 徐东平，E-mail:xudongping@yahoo.com
作者简介:朱华女，32岁，医学硕士，讲师。主要从事乙型肝炎重症化机制研究。E-mail: zhubaobao1213@126.com
基金资助:
国家“十一五”传染病重大专项课题（2008ZX10002-011）；北京市自然科学基金课题（7091006）

Hepatitis B virus rtN238H variant infection with adefovir resistance in patients with chronic hepatitis B

ZHU Hua，ZHONG Yanwei，XU Zhihui，et al.

Institute of Biotechnology，Guilin Medical College，Guilin 541004， Guangxi Zhuang Autonomous Region

Received:2011-04-20 Online:2011-10-15 Published:2016-04-14

摘要/Abstract

摘要： 目的阐明乙型肝炎病毒（HBV）多聚酶/逆转录酶区rtN238H 变异对临床产生阿德福韦（ADV）耐药的影响。方法分析了1789例慢性乙型肝炎患者rtN238H变异的发生频率及其与ADV用药的关系；从典型病例患者血清中克隆获得HBV rtN238H变异株并通过回复定点突变获得对应的野生株，分别构建pTriEx-HBV1.1重组表达载体，瞬时转染HepG2 细胞。给予转染细胞不同浓度ADV处理，用DNase消化游离DNA后，对上清中成熟病毒颗粒中的HBV DNA进行裂解定量以评价病毒的复制力。结果在1789例乙型肝炎患者中rtN238H变异为181例（10.1%），其中HBV B基因型感染为151例（83.4%），C基因型感染为30例（16.6%）；ADV经治和未治患者分别为130例（71.8.%）和51例（28.2%），其中对ADV治疗产生临床应答（含部分应答）的占82.3%（107/130），无应答或出现病毒学反跳的占17.7%（23/130），但与野生株相比，rtN238H变异株对ADV的敏感性和病毒复制力无明显的改变。结论 rtN238H是HBV自然发生的多态性变异，对ADV敏感性和复制力无直接的影响。

关键词: 慢性乙型肝炎, 乙型肝炎病毒, 变异, 耐药性, 阿德福韦

Abstract: Objective To elucidate the impact of hepatitis B virus rtN238H variant on adefovir resistance. Methods The rtN238H incidence and its relationship with adefovir（ADV）administration were analyzed in 1789 patients with chronic hepatitis B. The rtN238N variant from a representative case was cloned and its wild-type counterpart was acquired by reverse site-directed mutagenesis. pTriEx-HBV1. 1 vetors harboring N238H variant or wild-type strain were respectively constructed and transfected into HepG2 cells. The cells were treated with serial concentration of ADV. After digesting uncoated DNA with DNase，HBV DNA in viral particles in culture supernatant was released and quantitated by real-time PCR. Results One hundred and eighty one（10.1%）patients were identified as having rtN238H，out of them，151（83.4%）were genotype B，and 30（16.6%）were genotype C；130 ADV-treated patients（71.8.%）had higher incidence of rtN238H variant than 51 ADV-untreated patients（28.2%）；However，compared to wild-type strain，rtN238H had similar sensitivity to ADV and viral replication competence in vitro. Conclusion The rtN238H is a naturally-developed polymorphism without direct impact on ADV sensitivity and viral replication.

Key words: Hepatitis B, Hepatitis B virus, Variant, Drug resistance, Adefovir

朱华,钟彦伟,许智慧,刘佳慧,刘妍,苏何玲,徐东平. 乙型肝炎病毒rtN238H 变异与阿德福韦酯耐药的相关性研究^*[J]. 实用肝脏病杂志, 2011, 14(5): 327-329.

ZHU Hua，ZHONG Yanwei，XU Zhihui，et al.. Hepatitis B virus rtN238H variant infection with adefovir resistance in patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(5): 327-329.

参考文献

[1] PAPATHEODORIDIIS GV，MANOLAKOPOULOS S，DUSHEIKO G，et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection[J]. Lancet Infect Dis，2008，8（3）:1671-1678.
[2] LOK AS，ZOULIM F，SOCARMINNI S，et al. Antiviral drug-resistant HBV:standardization of nomenclature and assays and recommendations for management[J]. Hepatology，2007，46（1）:
254-265.
[3] BORROTO-ESODA K，MILLER MD，ARTERBUM S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials[J]. J Hepatol，2007，7（4）:492-498.
[4] QI X，XIONG S，YANG H，et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents[J]. Antivir Ther，2007，12（3）:355-362.
[5] SCHILDGEN O，SIRMA H，FUNK A，et al. Variant of hepatitis B virus with primary resistance to adefovir[J]. N Engl J Med，2006，54（17）:1807-1812.
[6] LACOMBE K，OLLIVET A，GOZLAN J，et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-coinfected patient[J]. Aids，2006，20:2229-2231.
[7] ILVIA G，VALERIA B，ANTONINA S，et al.Lamivudine-resistant chronic hepatitis B:An observational study on adefovir in monotherapy or in combination with lamivudine[J]. J Hepatol，2008，48（4）:540-547.
[8] 徐东平. 乙型肝炎病毒耐药的检测与判断[J]. 中华肝脏病杂志，2009，17:61-63.
[9] XU Z，LIU Y，XU T，et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus[J]. J Clin Virol，
2010，48（4）:270-274.
[10] LIU Y，ZHONG Y，ZOU Z，et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter precore region in 507 Chinese patients with acute and chronic hepatitis B[J]. J Clin Virol，2010，47（3）:243-247.
[11] JI D，LIU Y，SI LL，et al.Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients[J]. Clin Chim Acta，2011，412（3-4）:305-313.
[12] SORIANO V，PERELSON AS，ZOULIM F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses[J]. J Antimicrob Chemother，2008，62（1）:1-4.
[13] 徐东平，李进，张玲霞. 恩替卡韦治疗慢性乙型肝炎的研究进展[J]. 中华医学杂志，2006，86（28）:2014-2016.
[14] ZOULIM F. In vitro models for studying hepatitis B virus drug resistance[J]. Semin Liver Dis，2006，26（2）:171-180.
[15] 刘禄，郝瀚，刘永明，等. HBV表型耐药方法的建立及对临床分离株的表型耐药分析[J]. 解放军医学杂志，2010，35（6）:632-634.
[16] AMINI-BAVIL-OLYAEE S，HERBERS U，SHELDON J，et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains[J]. Hepatology，2009，49（4）:1158-1165.
[17] INOUE J，UENO Y，WAKUI Y，et al. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients:influence of hepatitis B virus genotype and resistance mutation pattern[J]. J Viral Hepat，2011，18（3）:206-215.
[18] LI X，WANG L，ZHONG Y，et al. Hepatitis B virus（HBV） subgenotypes C2 and B2 differ in lamivudine-and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients[J]. J Clin Microbiol，2010，48（12）:4363-4369.

乙型肝炎病毒rtN238H 变异与阿德福韦酯耐药的相关性研究^*

Hepatitis B virus rtN238H variant infection with adefovir resistance in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.